[go: up one dir, main page]

IE20130342A1 - Immunogenic compositions comprising a gp120 related polypeptide - Google Patents

Immunogenic compositions comprising a gp120 related polypeptide

Info

Publication number
IE20130342A1
IE20130342A1 IE20130342A IE20130342A IE20130342A1 IE 20130342 A1 IE20130342 A1 IE 20130342A1 IE 20130342 A IE20130342 A IE 20130342A IE 20130342 A IE20130342 A IE 20130342A IE 20130342 A1 IE20130342 A1 IE 20130342A1
Authority
IE
Ireland
Prior art keywords
composition according
suitably
clause
polypeptide
immunogenic composition
Prior art date
Application number
IE20130342A
Other languages
English (en)
Inventor
Patricia B Bourguignon
Marguerite Christine Koutsoukos
Clarisse Marie-Madeleine Lorin
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority to CA2851852A priority Critical patent/CA2851852A1/fr
Priority to BR102014011184A priority patent/BR102014011184A2/pt
Publication of IE20130342A1 publication Critical patent/IE20130342A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16HIV-1 ; HIV-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IE20130342A 2013-09-16 2013-11-08 Immunogenic compositions comprising a gp120 related polypeptide IE20130342A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2851852A CA2851852A1 (fr) 2013-09-16 2014-05-08 Nouvelles compositions
BR102014011184A BR102014011184A2 (pt) 2013-09-16 2014-05-09 composição imunogênica, métodos de tratamento ou profilaxia de infecção, para reduzir o risco de transmissão de hiv, e para produzir uma composição, kit, e, vetor viral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201316463A GB201316463D0 (en) 2013-09-16 2013-09-16 Novel compositions

Publications (1)

Publication Number Publication Date
IE20130342A1 true IE20130342A1 (en) 2015-03-25

Family

ID=49552735

Family Applications (1)

Application Number Title Priority Date Filing Date
IE20130342A IE20130342A1 (en) 2013-09-16 2013-11-08 Immunogenic compositions comprising a gp120 related polypeptide

Country Status (4)

Country Link
BE (1) BE1021315B1 (fr)
GB (1) GB201316463D0 (fr)
IE (1) IE20130342A1 (fr)
WO (1) WO2015036061A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN111032080A (zh) 2017-05-30 2020-04-17 葛兰素史密丝克莱恩生物有限公司 用于制造佐剂的新型方法
EP3717001A1 (fr) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Purification de saponine
EP3980044A1 (fr) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Purification de saponine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035555A1 (fr) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeres env de hiv/siv avec capacite de promotion de la trimerisation de maintien de cibles d'anticorps neutralisants
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
JP2013523617A (ja) * 2010-03-26 2013-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Hivワクチン

Also Published As

Publication number Publication date
BE1021315B1 (fr) 2015-10-28
GB201316463D0 (en) 2013-10-30
WO2015036061A1 (fr) 2015-03-19

Similar Documents

Publication Publication Date Title
CA2505583C (fr) Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination
JP2015012874A (ja) 改良されたワクチンおよびそれを使用するための方法
US20140234399A1 (en) Hiv vaccine
US11897919B2 (en) Multivalent HIV vaccine boost compositions and methods of use
US10729762B2 (en) HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
IE20130342A1 (en) Immunogenic compositions comprising a gp120 related polypeptide
US20210138062A1 (en) Compositions and methods to treat aids
US20070253979A1 (en) Immunogenic Hiv Compositions and Related Methods
CN116212012A (zh) 复合佐剂以及包含它的疫苗制剂
US8652459B2 (en) Splitting GP41
US20220305112A1 (en) Novel methods and uses
IE20130343A1 (en) Immunogenic compositions comprising a gp120 related polypeptide
CA2851852A1 (fr) Nouvelles compositions
BR102014011184A2 (pt) composição imunogênica, métodos de tratamento ou profilaxia de infecção, para reduzir o risco de transmissão de hiv, e para produzir uma composição, kit, e, vetor viral
KR20140116091A (ko) 돌연변이형 렌티바이러스 env 단백질 및 이의 약물로서의 용도
JP2009536653A (ja) Hiv−1免疫原性組成物
Fresneda-Mora et al. Relevancia del antígeno Gag para el desarrollo de candidatos vacunales contra el VIH-1
Fresneda-Mora et al. Relevance of the Gag antigen for developing vaccine candidates against HIV-1
US20130149323A1 (en) Mutated lentiviral env proteins and their use as drugs
KR20070019635A (ko) 면역원성 hiv 조성물 및 이와 관련된 방법

Legal Events

Date Code Title Description
FJ9A Application deemed to be withdrawn section 31(3)